Login to Your Account

BLA for Pharming's, Santarus' HAE Drug Refused by FDA

By Nuala Moran

Tuesday, March 1, 2011
LONDON – The FDA issued a refusal to file notice to Pharming NV and its partner Santarus Inc., for Rhucin, a recombinant protein product for treating hereditary angioedema (HAE), which is generated in the milk of transgenic rabbits.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription